Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Impact of Her2 and BRCA1/2 status in high-dose chemotherapy and autologous stem cells transplantation in the treatment of breast cancer: The Institut Paoli Calmettes' experience].
Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A. Boudin L, et al. Bull Cancer. 2017 Apr;104(4):332-343. doi: 10.1016/j.bulcan.2016.12.007. Epub 2017 Feb 16. Bull Cancer. 2017. PMID: 28214007 French.
[The concept of cancer stem cell].
Charafe-Jauffret E. Charafe-Jauffret E. Bull Cancer. 2017 Dec;104(12):1056-1059. doi: 10.1016/j.bulcan.2017.10.020. Epub 2017 Nov 21. Bull Cancer. 2017. PMID: 29169654 French. No abstract available.
[Cancer stem cells and precision medicine].
Charafe-Jauffret E. Charafe-Jauffret E. Bull Cancer. 2017 Dec;104(12):1088-1090. doi: 10.1016/j.bulcan.2017.10.021. Epub 2017 Nov 21. Bull Cancer. 2017. PMID: 29169655 French. No abstract available.
Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study.
Boudin L, Gonçalves A, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaeghel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Chabannon C. Boudin L, et al. J Cancer. 2016 Oct 23;7(14):2077-2084. doi: 10.7150/jca.15797. eCollection 2016. J Cancer. 2016. PMID: 27877223 Free PMC article.
CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer.
Fattori S, Le Roy A, Houacine J, Robert L, Abes R, Gorvel L, Granjeaud S, Rouvière MS, Ben Amara A, Boucherit N, Tarpin C, Pakradouni J, Charafe-Jauffret E, Houvenaeghel G, Lambaudie E, Bertucci F, Rochigneux P, Gonçalves A, Foussat A, Chrétien AS, Olive D. Fattori S, et al. Among authors: charafe jauffret e. Cancer Res. 2023 Sep 15;83(18):3026-3044. doi: 10.1158/0008-5472.CAN-23-0613. Cancer Res. 2023. PMID: 37379438 Free PMC article.
MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness.
Puppo M, Valluru MK, Croset M, Ceresa D, Iuliani M, Khan A, Wicinski J, Charafe-Jauffret E, Ginestier C, Pantano F, Ottewell PD, Clézardin P. Puppo M, et al. Among authors: charafe jauffret e. Br J Cancer. 2023 Sep;129(5):754-771. doi: 10.1038/s41416-023-02340-9. Epub 2023 Jul 13. Br J Cancer. 2023. PMID: 37443350 Free PMC article.
161 results